New-onset Diabetes is a Predictive Risk Factor for Pancreatic Lesions in High-risk Individuals: An Observational Cohort Study

Overview

Journal Endosc Ultrasound

Date 2024 Jul 1

PMID 38947744

Authors

Seyda Baydogan

Chirayu Mohindroo

Merve Hasanov

Maria F Montiel

Pompeyo Quesada

Irina M Cazacu

Adrianna A Luzuriaga Chavez

Maureen E Mork

Wenli Dong

Lei Feng

Y Nancy You

Banu Arun

Eduardo Vilar

Powel Brown

Matthew H G Katz

Suresh T Chari

Anirban Maitra

Eric P Tamm

Michael P Kim

Manoop S Bhutani

Florencia McAllister

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Pancreatic cancer (PC) is the third cause of cancer-related deaths. Early detection and interception of premalignant pancreatic lesions represent a promising strategy to improve outcomes. We evaluated risk factors of focal pancreatic lesions (FPLs) in asymptomatic individuals at hereditary high risk for PC.

Methods: This is an observational single-institution cohort study conducted over a period of 5 years. Surveillance was performed through imaging studies (EUS or magnetic resonance imaging/magnetic resonance cholangiopancreatography) and serum biomarkers. We collected demographic characteristics and used univariate and multivariate logistic regression models to evaluate associations between potential risk factors and odd ratios (ORs) for FPL development.

Results: A total of 205 patients completed baseline screening. Patients were followed up to 53 months. We detected FPL in 37 patients (18%) at baseline; 2 patients had lesions progression during follow-up period, 1 of them to PC. Furthermore, 13 patients developed new FPLs during the follow-up period. Univariate and multivariate analyses revealed that new-onset diabetes (NOD) is strongly associated with the presence of FPL (OR, 10.94 [95% confidence interval, 3.01-51.79; < 0.001]; OR, 9.98 [95% confidence interval, 2.15-46.33; = 0.003]). Follow-up data analysis revealed that NOD is also predictive of lesions progression or development of new lesions during screening (26.7% 2.6%; = 0.005).

Conclusions: In a PC high-risk cohort, NOD is significantly associated with presence of FPL at baseline and predictive of lesions progression or new lesions during surveillance.

References

Verna E, Hwang C, Stevens P, Rotterdam H, Stavropoulos S, Sy C . Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16(20):5028-37. DOI: 10.1158/1078-0432.CCR-09-3209. View

Sah R, Nagpal S, Mukhopadhyay D, Chari S . New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013; 10(7):423-33. PMC: 3932322. DOI: 10.1038/nrgastro.2013.49. View

Overbeek K, Levink I, Koopmann B, Harinck F, Konings I, Ausems M . Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2021; 71(6):1152-1160. PMC: 9120399. DOI: 10.1136/gutjnl-2020-323611. View

Everhart J, Wright D . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273(20):1605-9. View

Chari S, Leibson C, Rabe K, Ransom J, de Andrade M, Petersen G . Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005; 129(2):504-11. PMC: 2377196. DOI: 10.1016/j.gastro.2005.05.007. View

Bar-Mashiah A, Aronson A, Naparst M, Dimaio C, Lucas A . Elevated hemoglobin A1c is associated with the presence of pancreatic cysts in a high-risk pancreatic surveillance program. BMC Gastroenterol. 2020; 20(1):161. PMC: 7254640. DOI: 10.1186/s12876-020-01308-w. View

Low G, Panu A, Millo N, Leen E . Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics. 2011; 31(4):993-1015. DOI: 10.1148/rg.314105731. View

Vasen H, Wasser M, van Mil A, Tollenaar R, Konstantinovski M, Gruis N . Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2010; 140(3):850-6. DOI: 10.1053/j.gastro.2010.11.048. View

Cronin K, Ries L, Edwards B . The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014; 120 Suppl 23:3755-7. DOI: 10.1002/cncr.29049. View

10.

Tummala Md P, Rao Md S, Agarwal Md B . Differential Diagnosis of Focal Non-Cystic Pancreatic Lesions With and Without Proximal Dilation of Pancreatic Duct Noted on CT Scan. Clin Transl Gastroenterol. 2013; 4:e42. PMC: 3839021. DOI: 10.1038/ctg.2013.15. View

11.

Torisu Y, Takakura K, Kinoshita Y, Tomita Y, Nakano M, Saruta M . Pancreatic cancer screening in patients with presumed branch-duct intraductal papillary mucinous neoplasms. World J Clin Oncol. 2019; 10(2):67-74. PMC: 6390120. DOI: 10.5306/wjco.v10.i2.67. View

12.

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B . Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. PMC: 3148940. DOI: 10.1038/nature09515. View

13.

Del Chiaro M, Verbeke C, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J . Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. JAMA Surg. 2015; 150(6):512-8. DOI: 10.1001/jamasurg.2014.3852. View

14.

Munigala S, Singh A, Gelrud A, Agarwal B . Predictors for Pancreatic Cancer Diagnosis Following New-Onset Diabetes Mellitus. Clin Transl Gastroenterol. 2015; 6:e118. PMC: 4816040. DOI: 10.1038/ctg.2015.44. View

15.

Dbouk M, Katona B, Brand R, Chak A, Syngal S, Farrell J . The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022; 40(28):3257-3266. PMC: 9553376. DOI: 10.1200/JCO.22.00298. View

16.

Steinberg W . The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990; 85(4):350-5. View

17.

Shah I, Wadhwa V, Bilal M, Germansky K, Sawhney M . Prospective Assessment for Prediabetes and New-Onset Diabetes in High-Risk Individuals Undergoing Pancreatic Cancer Screening. Gastroenterology. 2021; 161(5):1689-1691.e1. DOI: 10.1053/j.gastro.2021.06.055. View

18.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

19.

Pannala R, Basu A, Petersen G, Chari S . New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2008; 10(1):88-95. PMC: 2795483. DOI: 10.1016/S1470-2045(08)70337-1. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View